AR056723A2 - Polipeptido purificado metodo para producirlo , metodo para identificarlo y/ o aislarlo composicion farmaceutica que lo comprende, secuencia de acidos nucleicos aislada que codifica dicho polipeptido, vector que contiene a dicha secuencia celula huesped transfectada por dicho vector, sonda nucleotid - Google Patents
Polipeptido purificado metodo para producirlo , metodo para identificarlo y/ o aislarlo composicion farmaceutica que lo comprende, secuencia de acidos nucleicos aislada que codifica dicho polipeptido, vector que contiene a dicha secuencia celula huesped transfectada por dicho vector, sonda nucleotidInfo
- Publication number
- AR056723A2 AR056723A2 ARP060104650A ARP060104650A AR056723A2 AR 056723 A2 AR056723 A2 AR 056723A2 AR P060104650 A ARP060104650 A AR P060104650A AR P060104650 A ARP060104650 A AR P060104650A AR 056723 A2 AR056723 A2 AR 056723A2
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptide
- ducted
- acid sequence
- vector
- nucleic acid
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 2
- 150000007523 nucleic acids Chemical group 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000523 sample Substances 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Polipéptido purificado, que comprende una secuencia de aminoácidos elegida entre: a) la secuencia SEC ID No.2, b) toda secuencia biologicamente activa derivada de SEC ID No. 2 y capaz de ligarse específicamente a la IL-13. Se proporciona además, un método para producirlo, un método para identificarlo y/o aislarlo, una composicion farmacéutica que lo comprende, la secuencia de ácidos nucléicos aislada que codifica a dicho polipéptido, También se proporciona un vector que contiene a dicha secuencia, una célula huésped transfectada con dicho vector, una sonda nucleotídica y una secuencia antisentido. Además se describen las utilizaciones de dicho polipéptido, secuencia y sonda.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9514424A FR2742156A1 (fr) | 1995-12-06 | 1995-12-06 | Polypeptide recepteur de l'il-13 |
| PCT/FR1996/001756 WO1997020926A1 (fr) | 1995-12-06 | 1996-11-07 | Polypeptide recepteur de l'il-i3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056723A2 true AR056723A2 (es) | 2007-10-17 |
Family
ID=9485198
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960105500A AR004860A1 (es) | 1995-12-06 | 1996-12-05 | Anticuerpos mono o policionales, anticuerpos conjugados, o sus fragmentos, su utilizacion y metodo de diagnostico in vitro de patologias correlacionadas con una expresion anormal del receptor de la il-13, a partir de muestras biologicas susceptibles de contener el receptor de la il-13 expresado a un nivel anormal |
| ARP060104650A AR056723A2 (es) | 1995-12-06 | 2006-10-25 | Polipeptido purificado metodo para producirlo , metodo para identificarlo y/ o aislarlo composicion farmaceutica que lo comprende, secuencia de acidos nucleicos aislada que codifica dicho polipeptido, vector que contiene a dicha secuencia celula huesped transfectada por dicho vector, sonda nucleotid |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960105500A AR004860A1 (es) | 1995-12-06 | 1996-12-05 | Anticuerpos mono o policionales, anticuerpos conjugados, o sus fragmentos, su utilizacion y metodo de diagnostico in vitro de patologias correlacionadas con una expresion anormal del receptor de la il-13, a partir de muestras biologicas susceptibles de contener el receptor de la il-13 expresado a un nivel anormal |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US7928073B2 (es) |
| EP (1) | EP0876482B1 (es) |
| JP (3) | JP3415162B2 (es) |
| AR (2) | AR004860A1 (es) |
| AT (1) | ATE234922T1 (es) |
| AU (1) | AU7576096A (es) |
| BR (1) | BR9611697B1 (es) |
| CA (1) | CA2238893C (es) |
| DE (1) | DE69626859T2 (es) |
| DK (1) | DK0876482T3 (es) |
| ES (1) | ES2192620T3 (es) |
| FR (1) | FR2742156A1 (es) |
| MX (1) | MX9804419A (es) |
| MY (1) | MY123740A (es) |
| NO (3) | NO324775B1 (es) |
| PT (1) | PT876482E (es) |
| TW (1) | TW565570B (es) |
| WO (1) | WO1997020926A1 (es) |
| ZA (1) | ZA9610238B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2238080C (en) * | 1995-10-23 | 2012-03-13 | Amrad Operations Pty. Ltd. | A novel haemopoietin receptor and genetic sequences encoding same |
| US6911530B1 (en) | 1995-10-23 | 2005-06-28 | Amrad Operations, Pty., Ltd. | Haemopoietin receptor and genetic sequences encoding same |
| US7078494B1 (en) | 1996-03-01 | 2006-07-18 | Genetics Institute, Llc | Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding |
| US5710023A (en) | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
| EP0812913A3 (en) * | 1996-06-12 | 1999-08-04 | Smithkline Beecham Corporation | HR-1 receptor, a receptor of the cytokine receptors family |
| WO1998010638A1 (en) * | 1996-09-10 | 1998-03-19 | Amrad Operations Pty. Ltd. | Therapeutic molecules |
| GB9625899D0 (en) * | 1996-12-13 | 1997-01-29 | Glaxo Group Ltd | Substances and their uses |
| US6743604B1 (en) | 1996-12-13 | 2004-06-01 | Smithkline Beecham Corporation | Substances and their uses |
| US6057128A (en) | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| US7198789B2 (en) | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| US7189400B2 (en) | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
| CA2235420A1 (en) | 1998-06-17 | 1999-12-17 | Paolo Renzi | Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
| WO2000036103A1 (en) | 1998-12-14 | 2000-06-22 | Genetics Institute, Inc. | Cytokine receptor chain |
| US7553487B2 (en) | 1998-12-14 | 2009-06-30 | Genetics Institute, Llc | Method and compositions for treating asthma |
| US20020197266A1 (en) * | 2000-02-08 | 2002-12-26 | Waldemar Debinski | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| WO2001077332A2 (en) * | 2000-04-07 | 2001-10-18 | Heska Corporation | Compositions and methods related to canine igg and canine il-13 receptors |
| EA011686B1 (ru) | 2002-07-15 | 2009-04-28 | Уайт | Способ модуляции развития и функций т-клеток-хелперов |
| ES2385038T3 (es) | 2003-12-23 | 2012-07-17 | Genentech, Inc. | Nuevos anticuerpos Anti-IL 13 y usos de los mismos |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| MX2007005083A (es) | 2004-10-29 | 2007-10-03 | Topigen Pharmaceuticals Inc | Oligonucleotidos antisentido para tratar alergias y proliferacion celular neoplastica. |
| JP2008520684A (ja) | 2004-11-17 | 2008-06-19 | アブジェニックス・インコーポレーテッド | Ｉｌ−１３に対する完全ヒトモノクローナル抗体 |
| GB0615881D0 (en) * | 2006-08-10 | 2006-09-20 | Univ Southampton | Novel peptide for treatment of asthma |
| CA2685123A1 (en) * | 2007-04-23 | 2008-10-30 | Wyeth | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
| EP2850093B1 (en) | 2012-01-27 | 2019-01-09 | The Board of Trustees of the Leland Stanford Junior University | Therapeutic il-13 polypeptides |
| US9738696B2 (en) | 2012-08-09 | 2017-08-22 | The Board Of Trustees Of The Leland Stanford Junior University | Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities |
| EP2970492B1 (en) | 2013-03-15 | 2019-05-08 | Wake Forest University Health Sciences | Antibodies against human and canine il-13ra2 |
| PL3044323T3 (pl) | 2013-09-13 | 2022-06-27 | F.Hoffmann-La Roche Ag | Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych |
| MY193481A (en) | 2013-09-13 | 2022-10-17 | Genentech Inc | Method and compositions comprising purified recombinant polypeptides |
| JP6936934B2 (ja) | 2013-09-24 | 2021-09-22 | メディシナ セラピューティクス インコーポレイテッド | インターロイキン−４受容体結合融合タンパク質及びその使用 |
| EP3694558B1 (en) | 2017-10-10 | 2024-04-10 | Medicenna Therapeutics Inc. | Il-4-fusion formulations for treatment of central nervous system (cns) tumors |
| WO2019239213A2 (en) | 2018-06-01 | 2019-12-19 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) * | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5596072A (en) * | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
| US5587459A (en) * | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
| US6911530B1 (en) * | 1995-10-23 | 2005-06-28 | Amrad Operations, Pty., Ltd. | Haemopoietin receptor and genetic sequences encoding same |
| US5710023A (en) * | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
-
1995
- 1995-12-06 FR FR9514424A patent/FR2742156A1/fr active Pending
-
1996
- 1996-11-07 DE DE69626859T patent/DE69626859T2/de not_active Expired - Lifetime
- 1996-11-07 EP EP96938273A patent/EP0876482B1/fr not_active Revoked
- 1996-11-07 ES ES96938273T patent/ES2192620T3/es not_active Expired - Lifetime
- 1996-11-07 WO PCT/FR1996/001756 patent/WO1997020926A1/fr not_active Ceased
- 1996-11-07 BR BRPI9611697-8B1A patent/BR9611697B1/pt not_active IP Right Cessation
- 1996-11-07 AU AU75760/96A patent/AU7576096A/en not_active Abandoned
- 1996-11-07 PT PT96938273T patent/PT876482E/pt unknown
- 1996-11-07 JP JP52101797A patent/JP3415162B2/ja not_active Expired - Fee Related
- 1996-11-07 DK DK96938273T patent/DK0876482T3/da active
- 1996-11-07 CA CA2238893A patent/CA2238893C/fr not_active Expired - Fee Related
- 1996-11-07 AT AT96938273T patent/ATE234922T1/de active
- 1996-12-02 MY MYPI96005058A patent/MY123740A/en unknown
- 1996-12-05 ZA ZA9610238A patent/ZA9610238B/xx unknown
- 1996-12-05 TW TW085115042A patent/TW565570B/zh not_active IP Right Cessation
- 1996-12-05 AR ARP960105500A patent/AR004860A1/es active IP Right Grant
-
1998
- 1998-06-03 MX MX9804419A patent/MX9804419A/es active IP Right Grant
- 1998-06-04 NO NO19982550A patent/NO324775B1/no not_active IP Right Cessation
-
2002
- 2002-09-18 JP JP2002271902A patent/JP3737793B2/ja not_active Expired - Fee Related
-
2005
- 2005-05-06 JP JP2005135217A patent/JP4185070B2/ja not_active Expired - Fee Related
- 2005-07-15 US US11/182,384 patent/US7928073B2/en not_active Expired - Fee Related
- 2005-07-15 US US11/183,599 patent/US20060035856A1/en not_active Abandoned
- 2005-07-18 US US11/185,230 patent/US20050282216A1/en not_active Abandoned
-
2006
- 2006-10-25 AR ARP060104650A patent/AR056723A2/es active IP Right Grant
-
2007
- 2007-08-03 NO NO20074034A patent/NO328197B1/no not_active IP Right Cessation
-
2009
- 2009-09-11 NO NO20092994A patent/NO331148B1/no not_active IP Right Cessation
-
2011
- 2011-02-15 US US13/027,425 patent/US8318910B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056723A2 (es) | Polipeptido purificado metodo para producirlo , metodo para identificarlo y/ o aislarlo composicion farmaceutica que lo comprende, secuencia de acidos nucleicos aislada que codifica dicho polipeptido, vector que contiene a dicha secuencia celula huesped transfectada por dicho vector, sonda nucleotid | |
| BRPI9909018B8 (pt) | processo para a síntese de um peptídeo | |
| ATE272109T1 (de) | Rekombinante collagenase typ i aus clostridium histolyticum und ihre verwendung zur isolierung von zellen und zellverbänden | |
| WO1996034107A3 (en) | Antiviral proteins, dna coding sequences therefor, and uses thereof | |
| AP1678A (en) | Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems. | |
| ATE335078T1 (de) | Überexpression von säugetier- und virusproteinen | |
| BR9814404A (pt) | " clonagem de expressão em fungos filamentosos " | |
| AR006188A1 (es) | "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion". | |
| EP0088195A3 (en) | Messenger rna, production and use thereof | |
| AR014891A1 (es) | Genes aislados de proteinas de membranas de mamiferos; reactivos relacionados | |
| ATE384787T1 (de) | Tripeptidyl-aminopeptidase | |
| EP0947583A3 (de) | Expressionsaktivierende Nukleinsäurefragmente des Melanom-inhibierenden Proteins (MIA) | |
| EP1380648A3 (en) | Recombinant DNAase B derived from streptococcus pyogenes | |
| KR970707162A (ko) | II종 포스포리파제 A2 저해작용을 갖는 신규한 모노클로날 항체 및 그 일부를 포함하는 단백질(Novel monoclonal antibody having inhibitory effect on type II phospholipase A2 and protein containing a part of the same) | |
| AU6338086A (en) | Method and means for sorting and identifying biological information | |
| FI961202A0 (fi) | Grb3-3-geeni, sen variantteja ja niiden käyttöjä | |
| BG104161A (en) | Recombinant expression of insulin c-peptide | |
| ATE291088T1 (de) | Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe | |
| ATE191223T1 (de) | Verwendung von zelladhäsions-peptiden zur modifikation des haftungsvermögens eukaryontischer zellen untereinander | |
| DE69828874D1 (de) | Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen | |
| ATE316138T1 (de) | Rekombinante expression von s-layer-proteinen | |
| DE69734596D1 (de) | "smoothened" proteine aus wirbeltieren | |
| SE9401380D0 (sv) | Ny celltillväxt-relaterad peptid och användning därav | |
| AUPM772494A0 (en) | Improvements in production of proteins in host cells | |
| DK0773999T3 (da) | OR-1, en orphan-receptor tilhørende kernereceptorfamilien |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |